Effect of Sucrose on Cisplatin-induced Fatigue-like Behavior in Mice: Comparison With Fructose and Glucose

Background/Aim: Fatigue is the most common symptom in patients with cancer undergoing radiation therapy or cancer chemotherapy. However, cancer-related fatigue remains undertreated and poorly understood. Materials and Methods: Mice were administered a single dose of cisplatin (10 mg/kg, intraperiton...

Full description

Bibliographic Details
Published in:Cancer Diagnosis and Prognosis
Main Author: Yoshizawa K.; Kurono R.; Sato H.; Ishijima E.; Nasu H.; Ferdaos N.; Suzuki H.; Negishi K.
Format: Article
Language:English
Published: International Institute of Anticancer Research 2021
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85147275866&doi=10.21873%2fcdp.10014&partnerID=40&md5=fe591cf2e0ddc8b1242c1eac21c480a1
Description
Summary:Background/Aim: Fatigue is the most common symptom in patients with cancer undergoing radiation therapy or cancer chemotherapy. However, cancer-related fatigue remains undertreated and poorly understood. Materials and Methods: Mice were administered a single dose of cisplatin (10 mg/kg, intraperitoneally) or saline (as a control) and then treated with sucrose, fructose, glucose (each at 500 or 5,000 mg/kg, orally), or saline (control) daily for 4 days. cisplatin-induced fatigue-like behavior was investigated by assessment of running activity on a treadmill. The influence of glucose intake on tumor growth was also examined in Lewis lung carcinoma (LLC)-bearing mice. Results: Administration of sucrose and glucose improved cisplatin-induced fatigue-like behavior in mice, whereas administration of fructose showed only slight antifatigue effects. Although glucose-fed mice showed increased tumor growth, this was balanced out by the powerful cytotoxicity of cisplatin. Conclusion: Sucrose, and especially glucose, may improve patient quality of life during treatment with anticancer agents by preventing fatigue without interfering with the antitumor effects of cisplatin. © 2021 International Institute of Anticancer Research www.iiar-anticancer.org.
ISSN:27327787
DOI:10.21873/cdp.10014